Beckley Foundation

Beckley Foundation
Name	Beckley Foundation
Formation	1998
Founder	Amanda Feilding
Type	Charity; Research institute
Headquarters	Oxfordshire, England
Fields	Psychedelic research; Neuroscience; Drug policy reform

Beckley Foundation

The Beckley Foundation is an Oxfordshire-based charitable research organization established to advance scientific understanding of psychoactive substances and to inform drug policy through interdisciplinary studies. Founded at the intersection of neuroscience, psychiatry, and public policy, the organization has convened laboratories, clinical trials, and international policy fora to evaluate compounds, mechanisms, and regulatory frameworks. It is notable for integrating experimental pharmacology with harm reduction initiatives and for collaborating with universities, hospitals, and multilateral institutions.

History

The organization was founded in 1998 by Amanda Feilding, linking early initiatives in psychopharmacology with advocacy for regulatory reform. In its early years it supported pilot studies on substances such as psilocybin and MDMA and partnered with academic groups at Imperial College London, University of Oxford, and Johns Hopkins University to mount neuroimaging and clinical protocols. Throughout the 2000s the foundation organized symposia that brought together investigators from National Institutes of Health, clinicians from Massachusetts General Hospital, and policy experts from United Nations Office on Drugs and Crime to discuss evidence-based approaches. In the 2010s it expanded into randomized controlled trials and mechanistic studies involving investigators affiliated with King's College London, UCL, and the Karolinska Institutet, while engaging with regulators such as the UK Home Office and ethics committees at major teaching hospitals.

Mission and Objectives

The foundation’s mission emphasizes rigorous investigation of consciousness-altering compounds and the translation of findings into humane regulatory models. Objectives include supporting experimental work on pharmacodynamics and pharmacokinetics with neuroimaging modalities like functional magnetic resonance imaging studies led in collaboration with teams from Harvard Medical School and Yale School of Medicine, assessing therapeutic applications in conditions treated at centers such as Mount Sinai Health System and Columbia University Irving Medical Center, and informing international policy debates in venues including the World Health Organization and the European Commission. It aims to produce data to guide clinicians at institutions such as Mayo Clinic and advisers to parliamentary committees in the House of Commons.

Research Programs

Research programs span basic neuroscience, clinical trials, and epidemiology. Basic programs have included neuroimaging and electrophysiology conducted with research groups from Massachusetts Institute of Technology, University of Cambridge, and ETH Zurich to probe mechanisms of action for substances like LSD and DMT. Clinical programs have supported Phase II trials for treatment-resistant depression at sites affiliated with Imperial College Healthcare NHS Trust and pilot psychotherapy protocols developed with teams at Columbia Psychiatry and Johns Hopkins School of Medicine. Harm-reduction epidemiology projects employed methods from investigators at University College London and University of California, Los Angeles to monitor outcomes among cohorts. The foundation has also supported metabolomics and receptor binding assays performed in laboratories connected to Scripps Research and Max Planck Institute for Psychiatry.

Policy and Advocacy

The foundation has been active in policy arenas, producing evidence briefs for bodies such as the European Monitoring Centre for Drugs and Drug Addiction and submitting testimony to legislative inquiries by committees in the United Kingdom and the European Parliament. It has convened roundtables with diplomats from the United Nations Commission on Narcotic Drugs and advisors from the Organisation for Economic Co-operation and Development to discuss rescheduling and therapeutic access. Advocacy efforts have coordinated with NGOs including Drug Policy Alliance and Transform Drug Policy Foundation and have influenced discussions among regulatory agencies like the Medicines and Healthcare products Regulatory Agency and the Food and Drug Administration.

Partnerships and Collaborations

Collaborative networks include universities, hospitals, think tanks, and industry partners. Academic partners have included Imperial College London, Johns Hopkins University, King's College London, and UCL, while clinical collaborators have involved Royal London Hospital and centers in the Netherlands and Portugal. Policy collaborations have engaged the Bevan Commission, civil society groups such as OPEN Foundation, and philanthropic funders associated with foundations like Wellcome Trust and Gates Foundation in related health policy domains. The foundation has also worked with contract research organizations and biotechnology firms in translational pathways.

Funding and Governance

Funding sources have combined philanthropic donations, research grants from public agencies such as the National Institutes of Health and charitable trusts, and project-specific support from foundations within the biomedical philanthropy sector. Governance comprises a board of trustees and scientific advisory boards featuring academics and clinicians from institutions including University of Oxford, Harvard University, and Karolinska Institutet. Ethical oversight and trial monitoring are coordinated with institutional review boards at partner hospitals and regulatory bodies including the UK Research Ethics Service.

Public Engagement and Education

Public engagement activities include conferences, policy briefings, and public lectures delivered in venues such as Royal Society-affiliated events and university lecture series at University of Oxford and Imperial College London. Educational outputs include white papers, briefing notes for parliamentary committees, and contributions to documentary projects broadcast in collaboration with media organizations including BBC and independent science publishers. The foundation has supported training workshops for clinicians from the American Psychiatric Association and continuing professional development aligned with major psychiatric congresses such as the World Psychiatric Association meetings.

Category:Psychedelic research organizations